BTIG Raises its Price Target on Rapport Therapeutics (RAPP)

Rapport Therapeutics, Inc. (NASDAQ:RAPP) is one of the 10 Stocks That Have the Potential to Rise 1000%.

On May 21, 2026, BTIG raised the firm’s price target on Rapport Therapeutics, Inc. (NASDAQ:RAPP) to $65 from $53 and maintained a Buy rating on the shares. BTIG cited clinical execution behind its more constructive stance on RAP-219 in bipolar mania, with Phase 2 topline results pulled forward to Q4 from the first half of FY27 due to steady, uniform enrollment.

On May 18, 2026, Truist assumed coverage of Rapport Therapeutics, Inc. (NASDAQ:RAPP) with a Buy rating and a price target of $56, up from $44. Truist said its thesis remains largely consistent with its prior view, seeing RAP-219 as an attractive, differentiated epilepsy asset. The firm cited early efficacy data suggesting best-in-category potential in focal onset seizures, along with upside optionality in bipolar mania that is not reflected in current projections.

Earlier in May, Rapport Therapeutics, Inc. (NASDAQ:RAPP) reported Q1 EPS of (42c), compared to the consensus estimate of (71c). Revenue totaled $20,000, below the consensus estimate of $6M. CEO Abraham N. Ceesay said Rapport entered 2026 with “strong momentum” across the RAP-219 development program, supported by Phase 2a follow-up data in focal onset seizures and progress toward Phase 3 trials. Ceesay also cited upcoming milestones in epilepsy, bipolar mania, and the company’s long-acting injectable formulation.

BTIG Raises its Price Target on Rapport Therapeutics (RAPP)

Africa Studio/Shutterstock.com

Rapport Therapeutics, Inc. (NASDAQ:RAPP) is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for central nervous system disorders.

While we acknowledge the risk and potential of RAPP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RAPP and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1